DDInter1472 DDInter119
Pioglitazone is an antihyperglycemic used as an adjunct to diet, exercise, and other antidiabetic medications to manage type 2 diabetes mellitus.[L11416,L11419,L11422,L11425] It is administered as a racemic mixture, though there is no pharmacologic difference between the enantiomers and they appear to interconvert _in vivo_ with little consequence. The thiazolidinedione class of medications, which also includes [rosiglitazone] and [troglitazone], exerts its pharmacological effect primarily by promoting insulin sensitivity and the improved uptake of blood glucose via agonism at the peroxisome proliferator-activated receptor-gamma (PPARγ). PPARs are ligand-activated transcription factors that are involved in the expression of more than 100 genes and affect numerous metabolic processes, most notably lipid and glucose homeostasis. Thiazolidinediones, including pioglit
Armodafinil is the enantiopure of the wakefulness-promoting agent modafinil (Provigil), and is indicated to improve wakefulness in adult patients with excessive sleepiness associated with obstructive sleep apnea (OSA), narcolepsy, or shift work disorder (SWD). Research has shown that armodafinil significantly improves driving simulator performance in patients with SWD. Armodafinil consists of the (−)-R-enantiomer of the racemic modafinil. Armodafinil is produced by the pharmaceutical company Cephalon Inc. (a wholly owned subsidiary of Teva Pharmaceutical Industries Ltd.) and was approved by the U.S. Food and Drug Administration (FDA) in June 2007.
Pioglitazone {u} (Compound) resembles {v} (Compound) Rosiglitazone
Pioglitazone {u} (Compound) treats {v} (Disease) type 2 diabetes mellitus
Pioglitazone {u} (Compound) binds {v} (Gene) CYP2D6
Pioglitazone {u} (Compound) upregulates {v} (Gene) GPC1
Pioglitazone {u} (Compound) is included by {v} (Pharmacologic Class) Thiazolidinediones
Pioglitazone {u} (Compound) downregulates {v} (Gene) RGS2
Pioglitazone {u} (Compound) causes {v} (Side Effect) Acute coronary syndrome
Pioglitazone {u} may cause a minor interaction that can limit clinical effects when taken with {v} Lipoic acid
Pioglitazone {u} may cause a minor interaction that can limit clinical effects when taken with {v} Norgestrel
Pioglitazone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Remdesivir
Pioglitazone (Compound) resembles Rosiglitazone (Compound)
Pioglitazone (Compound) treats type 2 diabetes mellitus (Disease)
Pioglitazone (Compound) binds CYP2D6 (Gene)
Pioglitazone (Compound) upregulates GPC1 (Gene)
Pioglitazone (Compound) is included by Thiazolidinediones (Pharmacologic Class)
Pioglitazone (Compound) downregulates RGS2 (Gene)
Pioglitazone (Compound) causes Acute coronary syndrome (Side Effect)
Pioglitazone may cause a minor interaction that can limit clinical effects when taken with Lipoic acid
Pioglitazone may cause a minor interaction that can limit clinical effects when taken with Norgestrel
Pioglitazone may cause a moderate interaction that could exacerbate diseases when taken with Remdesivir